Exicure (DE:2H0)
NASDAQ:2H0
2H0 Stock Chart & Stats
€4.08
€0.00(0.00%)
At close: 4:00 PM EST
€4.08
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€1.48 - €8.25
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€23.20M
Enterprise Value€23.14M
Total Cash (Recent Filing)€3.75M
Total Debt (Recent Filing)€176.00K
Price to Earnings (P/E)―
Beta-1.43
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding6,373,915
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)8.69
Price to Sales (P/S)0.00
P/FCF Ratio-3.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary SNA PlatformThe proprietary spherical nucleic acid (SNA) platform is a durable competitive asset: it enables differentiated nucleic-acid delivery and can be applied across oncology and immunology programs, supporting multiple candidate opportunities and partnership interest over time.
Leverage Reduced To Zero DebtElimination of debt materially lowers fixed financing obligations and short-term default risk, improving financial flexibility. This reduces cash drain from interest and preserves balance-sheet capacity to support R&D or partnership-driven growth over the medium term.
Phase 2 Milestone And Improved Economics With PartnerCompleting the Burixafor Phase 2 milestone and securing a $1M payment while increasing economic participation strengthens the collaboration and de-risks that program. It creates a structurally improved future revenue share pathway and validates program progression.
Bears Say
Persistent Heavy Cash BurnConsistently negative operating and free cash flow implies ongoing reliance on external financing, partnerships, or dilution. Heavy burn reduces runway and forces strategic trade-offs, creating a sustained solvency and execution risk until cash generation stabilizes.
Unstable, Near-zero Revenue BaseHighly volatile, largely non-recurring revenue undermines predictability of cash flows and planning. Without steady commercial or recurring licensing income, the company remains vulnerable to funding shortfalls and will struggle to self-fund development long term.
Significant Leadership And Board TurnoverRapid departures of CEO/CFO and multiple board changes elevate execution and governance risk. Such turnover can disrupt strategic continuity, slow fundraising or regulatory progress, and increase uncertainty around near-term program execution and partnerships.
Exicure News
2H0 FAQ
What was Exicure’s price range in the past 12 months?
Exicure lowest stock price was €1.48 and its highest was €8.25 in the past 12 months.
What is Exicure’s market cap?
Exicure’s market cap is €23.20M.
When is Exicure’s upcoming earnings report date?
Exicure’s upcoming earnings report date is May 20, 2026 which is in 43 days.
How were Exicure’s earnings last quarter?
Exicure released its earnings results on Mar 25, 2026. The company reported -€0.395 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.395.
Is Exicure overvalued?
According to Wall Street analysts Exicure’s price is currently Overvalued.
Does Exicure pay dividends?
Exicure does not currently pay dividends.
What is Exicure’s EPS estimate?
Exicure’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Exicure have?
Exicure has 6,373,915 shares outstanding.
What happened to Exicure’s price movement after its last earnings report?
Exicure reported an EPS of -€0.395 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.621%.
Which hedge fund is a major shareholder of Exicure?
Currently, no hedge funds are holding shares in DE:2H0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Exicure
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
Technical Analysis
Options Prices
Currently, No data available
---